Skip to main
  1. Stocks
  2. Pfizer
  3. Forecast
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 20%
Buy 20%
Hold 53%
Sell 7%
Strong Sell 0%

Bulls say

Pfizer is supported by a broad, diversified portfolio of prescription drugs and vaccines that generated roughly $60 billion in annual sales, with international markets contributing 40% of revenue and emerging markets adding another growth lever. Its 3Q 2026 results were strong enough to lift FY 2026 revenue guidance to $62.0-64.0 billion and EPS guidance to $2.95-3.05, reflecting resilient demand for key products such as Vyndamax, Eliquis, and Nurtec, even as some COVID and Prevnar pressure persists. Beyond the core franchise, the outlook is strengthened by a maturing pipeline and multiple catalysts, including MEVPRO-1 data around February 2027 and obesity updates by the end of 2026, while international Vyndamax appears more durable through 2029 under EU orphan exclusivity.

Bears say

Pfizer is viewed negatively because its core business faces multiple pressure points, including disappointing execution on key products such as Padcev, Comirnaty, and Paxlovid, alongside the risk of clinical or regulatory setbacks in pipeline assets like berobenatide, PF'3945, PF'4404, and mevrometostat. Its 2026 guidance already reflects about $1.1 billion of negative year-over-year revenue impact from loss of exclusivity, while operating margins could be squeezed if the base business deteriorates faster than expected and EPS growth slows. Additional concern comes from expected weakness in Prevnar sales in 3Q26, with headwinds from declining vaccination rates, lower birth rates, and U.S. government vaccine policy, alongside macro risks from drug pricing reform and tariff changes that may compress investor sentiment.

Pfizer (PFE) has been analyzed by 15 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 53% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Pfizer (PFE) Analyst Forecast & Price Prediction

Get the latest Pfizer (PFE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Pfizer (PFE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 15 analysts, Pfizer (PFE) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Pfizer (PFE) Analyst Forecast & Price Prediction

Get the latest Pfizer (PFE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Pfizer (PFE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PFE stock data and trends